Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Suppression of indoleamine-2,3-dioxygenase 1 expression by promoter hypermethylation in ER-positive breast cancer
Authors
Keywords
-
Journal
OncoImmunology
Volume 6, Issue 2, Pages e1274477
Publisher
Informa UK Limited
Online
2017-01-04
DOI
10.1080/2162402x.2016.1274477
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
- (2016) Jonathan M. Pitt et al. IMMUNITY
- Differential tumor infiltration by T-cells characterizes intrinsic molecular subtypes in breast cancer
- (2016) M. Miyan et al. Journal of Translational Medicine
- IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance
- (2016) David H. Munn et al. TRENDS IN IMMUNOLOGY
- Prenatal maternal stress and wheeze in children: novel insights into epigenetic regulation
- (2016) Saskia Trump et al. Scientific Reports
- A TDO2-AhR Signaling Axis Facilitates Anoikis Resistance and Metastasis in Triple-Negative Breast Cancer
- (2015) Nicholas C. D'Amato et al. CANCER RESEARCH
- Integrative analysis of 111 reference human epigenomes
- (2015) Anshul Kundaje et al. NATURE
- Expression profile of the human IDO1 protein, a cancer drug target involved in tumoral immune resistance
- (2015) Nathalie Vigneron et al. OncoImmunology
- Drug-Targeted Inhibition of Peroxisome Proliferator-Activated Receptor-gamma Enhances the Chemopreventive Effect of Anti-Estrogen Therapy
- (2015) Hongyan Yuan et al. Oncotarget
- Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR
- (2015) Ulrike M. Litzenburger et al. Oncotarget
- The UCSC Genome Browser database: 2015 update
- (2014) Kate R. Rosenbloom et al. NUCLEIC ACIDS RESEARCH
- IDO is highly expressed in breast cancer and breast cancer-derived circulating microvesicles and associated to aggressive types of tumors by in silico analysis
- (2014) M. T. Isla Larrain et al. TUMOR BIOLOGY
- Extensive Profiling of the Expression of the Indoleamine 2,3-Dioxygenase 1 Protein in Normal and Tumoral Human Tissues
- (2014) I. Theate et al. Cancer Immunology Research
- Trial watch: IDO inhibitors in cancer therapy
- (2014) Erika Vacchelli et al. OncoImmunology
- Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry
- (2013) Hatem Soliman et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Model of Tryptophan Metabolism, Readily Scalable Using Tissue-specific Gene Expression Data
- (2013) Anne-Kristin Stavrum et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4
- (2013) Rikke B. Holmgaard et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Exploring TCGA Pan-Cancer Data at the UCSC Cancer Genomics Browser
- (2013) Melissa S. Cline et al. Scientific Reports
- ERα positively regulated DNMT1 expression by binding to the gene promoter region in human breast cancer MCF-7 cells
- (2012) Jun-Feng Shi et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- An epigenetic mechanism for high, synergistic expression of indoleamine 2,3-dioxygenase 1 (IDO1) by combined treatment with zebularine and IFN-γ: Potential therapeutic use in autoimmune diseases
- (2012) Zhong-Tian Xue et al. MOLECULAR IMMUNOLOGY
- Tryptophan metabolism in breast cancers: molecular imaging and immunohistochemistry studies
- (2012) Csaba Juhász et al. NUCLEAR MEDICINE AND BIOLOGY
- Reversal of tumoral immune resistance by inhibition of tryptophan 2,3-dioxygenase
- (2012) L. Pilotte et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development
- (2012) Courtney Smith et al. Cancer Discovery
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Genome-wide Methylation Analysis Identifies Genes Specific to Breast Cancer Hormone Receptor Status and Risk of Recurrence
- (2011) M. J. Fackler et al. CANCER RESEARCH
- DNA methylation profiling reveals a predominant immune component in breast cancers
- (2011) Sarah Dedeurwaerder et al. EMBO Molecular Medicine
- High expression of indoleamine 2,3-dioxygenase in the tumour is associated with medullary features and favourable outcome in basal-like breast carcinoma
- (2011) Jocelyne Jacquemier et al. INTERNATIONAL JOURNAL OF CANCER
- An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
- (2011) Christiane A. Opitz et al. NATURE
- Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
- (2011) Vinod P Balachandran et al. NATURE MEDICINE
- Estrogen and ERα: Culprits in cervical cancer?
- (2010) Sang-Hyuk Chung et al. TRENDS IN ENDOCRINOLOGY AND METABOLISM
- Supervised Risk Predictor of Breast Cancer Based on Intrinsic Subtypes
- (2009) Joel S. Parker et al. JOURNAL OF CLINICAL ONCOLOGY
- Estrogen Receptor Alpha Represses Transcription of Early Target Genes via p300 and CtBP1
- (2009) F. Stossi et al. MOLECULAR AND CELLULAR BIOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search